Hodgkin Lymphoma Pipeline

DelveInsight’s, “Hodgkin Lymphoma - Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hodgkin Lymphoma Understanding

Hodgkin Lymphoma: Overview

Hodgkin Lymphoma also known as Hodgkin disease is a type of blood cancer that initiate in the lymphatic system (part of immune system that help to get rid of waste and fight against infections). This disease is the most common type of cancer of lymphatic system. Hodgkin disease originate in the WBCs and grow abnormally and spread beyond the lymphatic system. As the disease progress it invades into other organs and can damage their function. Hodgkin’s lymphoma are more common in men than women and affect individuals between the age of 15-40 and above 55 years. The exact etiology of Hodgkin’s Lymphoma is not clear however, DNA mutation, and infection of Epstein-Barr virus (EBV), which causes mononucleosis can be the reason behind the development of Hodgkin’s lymphoma.

The most common symptoms of Hodgkin’s lymphoma are painless swollen lymph nodes in the neck, underarm or groin others may also include persistent fatigue, unexplained fever, drenching night sweats, sudden and unexplained weight loss, itchy skin (pruritus) swelling, pain around belly (abdominal) region and chest pain. There are four stages of this disease depending upon the diagnosis this further decides the treatment plan for the patient. 

 

The diagnosis of the Hodgkin’s Lymphoma includes tests to identify the changes in the body of the person the tests may include blood tests that comprises of Complete blood count (CBC), Blood chemistry study, Erythrocyte sedimentation rate (ESR) secondly the imaging tests that includes CT Scans, MRI, PET scans and ultrasound apart from these lymph node biopsy is also performed to analyze the chances of the disease. Based upon the diagnosis tests done and also on identification on which stage is particular lymphoma treatment plans are designed. There are several types of treatments for Hodgkin lymphomas these treatments either kill cancer cells or keep them from dividing each treatment has different side effects. Some are as follows Chemotherapy, Radiation therapy, Immunotherapy this treatment, also called biologic therapy or biotherapy, boosts the body’s immune system. Checkpoint inhibitors are an important part of this class of treatment for Hodgkin lymphoma. Targeted therapy uses medication or other substances to attack cancer cells. Targeted therapy may include treatments such as antibody-drug conjugates. Chemotherapy with stem cell transplantation. 

 

"Hodgkin Lymphoma - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hodgkin Lymphoma pipeline landscape is provided which includes the disease overview and Hodgkin Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Hodgkin’s Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hodgkin Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hodgkin’s Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Hodgkin Lymphoma.

Hodgkin Lymphoma Emerging Drugs Chapters

This segment of the Hodgkin Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Hodgkin Lymphoma Emerging Drugs

 

AB-205: Angiocrine Bioscience

AB-205 is a first-in-class engineered cell therapy consisting of proprietary 'universal' E-CEL (human engineered cord endothelial) cells. The AB-205 cells are intravenously administered after the completion of HDT on the same day as when the patient's own (autologous) blood stem cells are infused. AB-205 acts promptly to repair injured vascular niches of organs damaged by HDT. By repairing the vascular niches, AB-205 restores the natural process of tissue renewal, vital for organs such as oral-GI tract and the bone marrow. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hodgkin's Lymphoma.

 

Magrolimab: Gilead Sciences

Magrolimab is a humanized IgG4 subclass monoclonal antibody. The drug candidate is administered through intravenous route. It acts by targeting CD47 antigen and works as CD47 antigen inhibitors, antibody-dependent cell cytotoxicity. Currently being evaluated in the Phase II studies.

 

AUR105 : Aurigene Oncology

AUR105 is an oral, small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). AUR-105 had been found to be safe in preclinical toxicology evaluations, at several fold of anticipated efficacious doses in humans. Currently, the drug is being evaluated in Phase I for the treatment of Hodgkin’s Lymphoma.

Further product details are provided in the report……..

Hodgkin Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Hodgkin Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Hodgkin Lymphoma

There are approx. 15+ key companies which are developing the therapies for Hodgkin’s Lymphoma. The companies which have their Hodgkin Lymphoma drug candidates in the mid to advanced stage, i.e. phase III include, Angiocrine Bioscience

 

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

•  
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides 
• Polymer 
• Small molecule
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hodgkin Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hodgkin Lymphoma therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hodgkin Lymphoma drugs.

Hodgkin Lymphoma Report Insights

• Hodgkin Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hodgkin Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hodgkin Lymphoma drugs?
• How many Hodgkin Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hodgkin Lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hodgkin Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hodgkin Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?